Beam Therapeutics Inc. (BEAM) vs Recursion Pharmaceuticals, Inc. (RXRX)
A side-by-side comparison of Beam Therapeutics Inc. and Recursion Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 2, 2026. Differences are shown without an overall score or investment verdict.
BEAM
Beam Therapeutics Inc.
$24.38HealthcareDelayed quote: Oct 2, 2026, 3:40 PM EDT
RXRX
Recursion Pharmaceuticals, Inc.
$4.08HealthcareDelayed quote: Oct 2, 2026, 3:40 PM EDT
Total return — BEAM vs RXRX
growth of $100 · dividends reinvested · last 5yBEAM -68.1% (-20.4%/yr)RXRX -77.4% (-25.7%/yr)BEAM compounded faster over this window
BEAM RXRX
BEAM vs RXRX: by the numbers
- •BEAM is the larger company ($2.51B vs $2.14B market cap).
- •Both run net losses; BEAM's is the smaller (-54.75% vs -945.92% net margin).
- •BEAM grew revenue faster over the past five years (479.04% vs 45.50% CAGR).
Metrics side by side
Valuation
| Metric | BEAM | RXRX |
|---|---|---|
| P/S ratio | 16.08 | 39.05 |
| P/B ratio | 2.35 | 2.34 |
Profitability
| Metric | BEAM | RXRX |
|---|---|---|
| Gross margin | 84.05% | -61.96% |
| Operating margin | -274.57% | -867.87% |
| Net margin | -54.75% | -945.92% |
| ROE | -8.00% | -56.71% |
| ROIC | -28.96% | -49.78% |
Growth (annualized)
| Metric | BEAM | RXRX |
|---|---|---|
| Revenue CAGR (5Y) | 479.04% | 45.50% |
| Total return CAGR (5Y) | -22.35% | -28.56% |
Frequently asked
- Which has grown faster, BEAM or RXRX?
- Over the past five years, BEAM grew revenue faster — BEAM at a 479.04% CAGR versus RXRX at 45.50%.
- How have BEAM and RXRX total returns compared?
- Over the past 5 years, BEAM delivered -22.35% and RXRX delivered -28.56% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Beam Therapeutics ROERecursion Pharmaceuticals ROEBeam Therapeutics operating marginRecursion Pharmaceuticals operating marginBeam Therapeutics revenue growthRecursion Pharmaceuticals revenue growthBeam Therapeutics free cash flowRecursion Pharmaceuticals free cash flow
Beam Therapeutics & Recursion Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 2, 2026.